AstraZeneca receives China’s NMPA approval for Forxiga
21 Aug 2023
Drug ApprovalPhase 3
Preview
Source: Pharmaceutical Technology
AstraZeneca’s Forxiga is indicated for treating individuals with chronic kidney disease, type 2 diabetes and HFrEF in more than 100 countries globally. Credit: AstraZeneca.
AstraZeneca has received approval from China’s National Medical Products Administration (NMPA) for Forxiga (dapagliflozin) to reduce the risk of cardiovascular mortality, hospital admission for heart failure (HF), or urgent HF visits.
The treatment is indicated for usage in adult patients with symptomatic chronic HF.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsChina Contract Manufacturing Market Outlook - Trends, Ambitions, Key Players, Investment and Valu... GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - TRV-734 in Opium Withdrawal Syndrome GlobalData
View allCompanies IntelligenceAstraZeneca PlcNational Medical Products AdministrationView all
The latest development is based on positive data from the Phase III DELIVER clinical trial.
Based on data from the pooled analysis of the Phase III DELIVER and DAPA-HF trials, dapagliflozin is the first HF therapy to show a mortality benefit in complete ejection fraction ranges.
Forxiga can now be used in the region for adults with symptomatic chronic HF, irrespective of their ejection fraction status.
AstraZeneca executive vice-president and biopharmaceuticals business unit president Ruud Dobber stated: “This broader indication for Forxiga in adults with symptomatic chronic heart failure across the full ejection fraction range is a significant advancement for patients.
“It represents an exciting turning point in the battle against heart failure, given the unmet treatment needs and the absence until now of treatments that reduce mortality in this setting.”
In February 2023, the European Commission approved Forxiga to treat symptomatic chronic HFrEF.
Forxiga is an oral, once-a-day human sodium-glucose co-transporter 2 (SGLT2) inhibitorsodium-glucose co-transporter 2 (SGLT2) inhibitor.
It is indicated for treating individuals with chronic kidney disease, type 2 diabetes and HFrEF in more than 100 countries globally.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.